Hinova Pharmaceuticals (SH:688302) Ge Long Hui·2025-12-07 08:41Core Viewpoint - Haichuang Pharmaceutical's self-developed drug, Deutetrabenazine soft capsules, has been included in the National Medical Insurance Drug List for 2025, marking a significant recognition of its clinical value and innovation by the National Healthcare Security Administration [1] Group 1 - The inclusion of Deutetrabenazine soft capsules in the National Medical Insurance Drug List will facilitate market promotion and reduce the financial burden on patients, enhancing drug accessibility [1] - The National Medical Insurance Drug List will be officially implemented starting January 1, 2026, and the company will actively cooperate to promote the implementation of insurance policies [1] - The company aims to expand hospital access and core market coverage to better meet patient medication needs [1]